Clorox: Leading Consumer Staple - Lowest Valuation Since 2014, Highest Dividend Since 1983

CLX is the kind of name that can work in a late-cycle tape not because earnings suddenly accelerate, but because the market starts paying up for visibility when macro confidence deteriorates. The setup is less about immediate fundamental inflection and more about a multiple normalization trade: if investors continue crowding into cash-return defensives, the stock can rerate faster than the underlying business improves. The real second-order effect is on capital allocators inside consumer staples — peers with weaker balance sheets or less credible payout support may be forced to defend dividends or buybacks more aggressively, narrowing relative valuation gaps.

The main risk is that the “defensive premium” becomes a value trap if volume weakness persists and pricing power is less durable than the market is assuming. In that scenario, the stock can stay cheap for multiple quarters even while the dividend screens attractive, especially if private-label competition keeps pressure on shelf space and mix. A stronger-than-expected consumer rebound is also a headwind to the thesis, because it would rotate flows back into cyclicals and away from low-volatility income names.

From a timing perspective, this is a months-to-years idea, not a days-to-weeks catalyst trade. The best catalyst path is either a broader risk-off correction that reasserts the stock’s defensiveness, or confirmation that cash returns remain supported despite muted top-line growth. The contrarian point is that consensus may be underestimating how much downside is already discounted; if the market has fully priced in stagnation, even modest operating stability can unlock multiple expansion.